Pharmabiz

AstraZeneca’s Saphnelo approved in EU for subcutaneous self-administration as a new pre-filled pen for systemic lupus erythematosus

AstraZeneca’s Saphnelo (anifrolumab) has been approved in the European Union (EU) for subcutaneous self-administration as a pre-filled pen for adult patients with systemic lupus erythematosus (SLE) on ...
TipRanks on MSN

AstraZeneca’s Saphnelo approved in EU for subcutaneous self-admin

Saphnelo has been approved in the European Union, EU, for subcutaneous self-administration as a pre-filled pen for adult ...
The Pharma Letter

Saphnelo approved in the EU for sc self-administration

UK pharma major AstraZeneca today revealed that Saphnelo (anifrolumab) has been approved in the European Union (EU) for ...
Managed Healthcare Executive

New self-injectable biologics promise cost savings and patient convenience

Drug approvals this year have reflected the trend in clinical development of biologics shifting from intravenous to subcutaneous administration, offering shorter injection times, home use, and cost ...
Drug Store News

Sandoz offers generic Remodulin for subcutaneous administration

Sandoz is offering treprostinil injection for subcutaneous administration to treat patients diagnosed with pulmonary arterial hypertension. Sandoz treprostinil injection was the first generic of ...
MedPage Today

Subcutaneous Alzheimer's Drug May Be on the Horizon

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Weekly ...
Yahoo Finance

Global Subcutaneous Biologics Market to Surpass USD 236 Billion with Advancements in Self-Administration Devices and Drug Delivery Technologies

Dublin, April 01, 2025 (GLOBE NEWSWIRE) -- The "Subcutaneous Biologics Market, Industry Trends and Global Forecasts to 2035: Type of Biologic, Type of Therapy, Method of Administration, Fundamental ...
Targeted Oncology

Subcutaneous Cevostamab Shows Early Promise in R/R Myeloma

Cevostamab demonstrated a 38.8% overall response rate in relapsed/refractory multiple myeloma, with a median response duration of 12.3 months. BCMA-naive patients showed a higher overall response rate ...

Quebec becomes first province in Canada to list new subcutaneous OPDIVO® on public drug plan for solid tumour indications

Bristol Myers Squibb Canada (BMS) is pleased to announce that OPDIVO® SC (nivolumab for subcutaneous injection) is now included on the Liste des Médicaments-Établissements. Quebec is the first ...
Healio

Positive results in lung cancer show benefits of subcutaneous bispecifics

Please provide your email address to receive an email when new articles are posted on . Subcutaneous delivery reduced administration time from several hours to less than 5 minutes. Although unexpected ...
Nature

Subcutaneous administration of ghrelin stimulates energy intake in healthy lean human volunteers

The gastric hormone ghrelin appears a useful agent to stimulate food intake in people with anorexia of illness. The loss of ghrelin's acyl group renders it inactive, thus it has been thought that ...
PharmiWeb

Saphnelo approved in the EU for subcutaneous self-administration as a new pre-filled pen for systemic lupus erythematosus

Convenient subcutaneous option has potential to reach more patients with same clinical benefits as Saphnelo IV infusionAstraZeneca’s Saphnelo (anifrolumab) has been approved in the European Union (EU) ...